#2-88E. Rheumatology’s Renaissance: From Symptom Control to Precision Medicine (BestPractResClinRheumatol, 2025)

Are we witnessing the end of reliance on broad immunosuppression and corticosteroids in rheumatology? In this episode, we explore "Novel Therapy," a pivotal editorial that maps the transformative landscape of rheumatic disease management. The authors introduce a special collection of reviews detailing the seismic shift from symptomatic palliation to precision medicine, driven by breakthroughs in immunology and molecular biology across a spectrum of conditions, including rheumatoid arthritis, SLE, and traditionally refractory diseases like osteoarthritis. The most critical clinical takeaway is the accelerating move toward glucocorticoid minimization and the rigorous management of comorbidities, such as cardiovascular risks, treating them with the same urgency as the primary disease. While promising, clinicians must critically evaluate the long-term safety profiles of these novel agents and the logistical hurdles of implementing high-cost, complex therapies into equitable clinical practice. This article is vital for physicians to navigate the transition from standard care to personalized, mechanism-driven interventions that aim not just for remission, but for the restoration of immune homeostasis.

Citation: Kishimoto, M. and Nash, P. Novel Therapy. Best Practice & Research Clinical Rheumatology. 2025. DOI: 10.1016/j.berh.2025.102103

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.